Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IIIB, Single Arm Study, of Durvalumab in Combination With Platinum-Etoposide for Untreated Patients With Extensive-Stage Small Cell Lung Cancer Reflecting Real World Clinical Practice in Spain (CANTABRICO).

NCT04712903 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT04712903
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04712903 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IIIB, Single Arm Study, of Durvalumab in Combination With Platinum-Etoposide for Untreated Patients With Extensive-Stage Small Cell Lung Cancer Reflecting Real World Clinical Practice in Spain (CANTABRICO).
Lead sponsor
AstraZeneca
Phase
Phase 3
Overall status
Completed
Start date
December 16, 2020
Completion date
June 21, 2023
Enrollment
101 (actual)
Sites
34

Conditions

As the registry lists them; a condition with its own page is linked.

small cell lung carcinoma extensive disease